Abraham Morgentaler, MD
Director and Founder, Men's Health Boston
Associate Clinical Professor of Urologic Surgery
Harvard Medical School
Boston, Massachusetts

Urologists, endocrinologists, primary care physicians, cardiologists, and specialists interested in the management and treatment of hypogonadism.

Hypogonadism and erectile dysfunction (ED) are underdiagnosed and therefore undertreated conditions that can be associated with serious comorbid conditions, including metabolic and cardiovascular disease (CVD). Appropriate screening for comorbidities and treatment by any provider seeing men who are at risk should be encouraged. Mounting evidence indicates that ED and hypogonadism are associated with premature CVD, cardiovascular events, and cardiac death, as well as increased all-cause mortality. Despite compelling evidence, many clinicians are not aware of the connections between ED, hypoogonadism, comorbid conditions, and overall health.

At the conclusion of this activity, participants should be better able to:

  1. Examine current data on the relationship between cardiovascular disease and serum testosterone levels, and the effect of testosterone therapy on cardiometabolic parameters
  2. Recognize that, because erectile dysfunction (ED) and hypogonadism are markers for latent cardiometabolic disease, sexual function should be incorporated into cardiovascular disease (CVD) risk assessment for all men, as ED may identify those at higher risk who require further cardiovascular workup
  3. Employ current data on the relationship between ED, CVD, endogenous testosterone levels, and endothelial function when discussing management strategies and treatment decisions with the patient

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Dannemiller and CogniMed Inc. Dannemiller is accredited by the ACCME to provide continuing medical education for physicians.

Dannemiller designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

There is no charge for this activity. Statements of Credit will be provided by e-mail following activity participation and upon completion and electronic submission of the posttest and evaluation to Dannemiller. A link to the evaluation form is provided upon completion of the activity. If you have any questions about your certificate, please e-mail cme@dannemiller.com.

To resolve identified/potential conflicts of interest, the education content was fully reviewed by a physician member of the Dannemiller Clinical Content Review Committee who have no financial relationships with commercial interests. The resulting certified activity was found to provide educational content that is current, evidence based and commercially balanced.

It is the policy of Dannemiller to ensure fair balance, independence, objectivity, and scientific rigor in all programming. All faculty participating in sponsored programs are expected to identify and reference off-label product use and disclose any significant relationships with those supporting the activity or any others whose products or services are discussed. The faculty for this activity have disclosed that there will not be discussion about the use of products for non–FDA-approved indications.

In accordance with the Accreditation Council for Continuing Medical Education standards, parallel documents from other accrediting bodies, and Dannemiller policy, the following disclosures have been made:

Dannemiller Staff
Mark T. Nadeau, MD, MBA, FAAFP, Clinical Content Reviewer, has nothing to disclose.
Gordon Ringler, Project Manager, has nothing to disclose.

CogniMed Inc. Staff
Estelle Perera, Senior Director, Scientific Affairs and Program Design, and Medical Writer, has nothing to disclose.
Curlyn Larmony, Associate Program Manager, has nothing to disclose.

Abraham Morgentaler, MD, Director and Founder, Men's Health Boston, is an Associate Clinical Professor of Surgery (Urology) at Harvard Medical School; He is a Consultant for Auxilium Pharmaceuticals, Inc., Antares Pharma Inc. and AbbVie Inc.; He is an Investigator for Auxilium Pharmaceuticals, Inc., Antares Pharma Inc., Lilly USA, LLC and Wagner Chilcott; He is a Stockholder at Sprout Pharmaceuticals, Inc. The ideas and opinions presented in this educational activity are those of the faculty and do not necessarily reflect the views of Dannemiller and/or its agents. As in all educational activities, we encourage the practitioners to use their own judgment in treating and addressing the needs of each individual patient, taking into account that patient's unique clinical situation. Dannemiller disclaims all liability and cannot be held responsible for any problems that may arise from participating in this activity or following treatment recommendations presented.

This activity is supported by independent educational grants provided by Endo Pharmaceuticals, Inc. and Lilly USA, LLC.

This activity is an enduring material and consists of an audio recording and a written piece. Successful completion is achieved by listening to the audio or reading the piece, reflecting on the content's implications in your practice, and completing the assessment component.

The estimated time to complete this activity is 0.50 hour.

To receive credit for this activity, participants must complete the post-test with a passing score of 80% and then complete the evaluation.

This activity was originally released January 10, 2014, and is eligible for credit through January 10, 2015.

This activity was reviewed by an impartial content reviewer and by faculty. Faculty have final editorial control over the piece.

Privacy Policy | System Requirements

© 2014 CogniMed Inc. All rights reserved.            TU15147             January 2014